[go: up one dir, main page]

WO2024092160A3 - Protéases bifonctionnelles et leurs utilisations - Google Patents

Protéases bifonctionnelles et leurs utilisations Download PDF

Info

Publication number
WO2024092160A3
WO2024092160A3 PCT/US2023/077959 US2023077959W WO2024092160A3 WO 2024092160 A3 WO2024092160 A3 WO 2024092160A3 US 2023077959 W US2023077959 W US 2023077959W WO 2024092160 A3 WO2024092160 A3 WO 2024092160A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteases
bifunctional
targeted
sheddases
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/077959
Other languages
English (en)
Other versions
WO2024092160A2 (fr
Inventor
Yiqun Bai
Liam Michael CASEY
John Daniel MENDLEIN
Ayse Jane MUNIZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flagship Pioneering Innovations VII Inc
Original Assignee
Flagship Pioneering Innovations VII Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations VII Inc filed Critical Flagship Pioneering Innovations VII Inc
Publication of WO2024092160A2 publication Critical patent/WO2024092160A2/fr
Publication of WO2024092160A3 publication Critical patent/WO2024092160A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Les compositions et les procédés de l'invention sont utiles pour générer et utiliser des protéases bifonctionnelles (par exemple, des sheddases, des protéases ou des enzymes de dégradation de bêta-amyloïde (Aβ) ciblées) qui clivent des polypeptides d'une manière ciblée.
PCT/US2023/077959 2022-10-26 2023-10-26 Protéases bifonctionnelles et leurs utilisations Ceased WO2024092160A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263419458P 2022-10-26 2022-10-26
US63/419,458 2022-10-26

Publications (2)

Publication Number Publication Date
WO2024092160A2 WO2024092160A2 (fr) 2024-05-02
WO2024092160A3 true WO2024092160A3 (fr) 2024-05-30

Family

ID=90832102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077959 Ceased WO2024092160A2 (fr) 2022-10-26 2023-10-26 Protéases bifonctionnelles et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2024092160A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286367A1 (en) * 1996-07-15 2010-11-11 Adprotech Limited Conjugates of soluble peptidic compounds with membrane-binding agents
WO2011008260A2 (fr) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
US20160223532A1 (en) * 2013-09-11 2016-08-04 Agenus Inc. High throughput screening for biomolecules
WO2021211467A1 (fr) * 2020-04-13 2021-10-21 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286367A1 (en) * 1996-07-15 2010-11-11 Adprotech Limited Conjugates of soluble peptidic compounds with membrane-binding agents
WO2011008260A2 (fr) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
US20160223532A1 (en) * 2013-09-11 2016-08-04 Agenus Inc. High throughput screening for biomolecules
WO2021211467A1 (fr) * 2020-04-13 2021-10-21 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMOURES BÉATRICE, SIEGFRIED GÉRALDINE, KHATIB ABDEL-MAJID: "PCSK1 (proprotein convertase subtilisin/kexin type 1)", ATLAS OF GENETICS AND CYTOGENETICS IN ONCOLOGY AND HAEMATOLOGY, UNIVERSITY HOSPITAL, no. 6, XP093178890, ISSN: 1768-3262, DOI: 10.4267/2042/68910 *
LICHTENTHALER STEFAN F, LEMBERG MARIUS K, FLUHRER REGINA: "Proteolytic ectodomain shedding of membrane proteins in mammals—hardware, concepts, and recent developments", THE EMBO JOURNAL / EUROPEAN MOLECULAR BIOLOGY ORGANIZATION, IRL PRESS, OXFORD, vol. 37, no. 15, 1 August 2018 (2018-08-01), Oxford , XP093178888, ISSN: 0261-4189, DOI: 10.15252/embj.201899456 *

Also Published As

Publication number Publication date
WO2024092160A2 (fr) 2024-05-02

Similar Documents

Publication Publication Date Title
USD511990S1 (en) Diamond cut
WO2004028475A3 (fr) Analogues du glycosylceramide
WO2005056782A3 (fr) Perhydrolase
WO2024033135A3 (fr) Variants d'amylase
WO2005111203A3 (fr) $g(a)-amylases mutantes
AU2003299585A1 (en) Water-soluble products and methods of making and using the same
EP1395398B8 (fr) Ensemble de liens pour bras robotique similaire a un serpent
WO2007030567A3 (fr) Composes actifs sur les ppar
WO2002095007A3 (fr) Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques
TW200730865A (en) Optical element, manufacturing process for this and composite combination of component with the optical element
GB9717905D0 (en) Lipid-containing compositions and uses thereof
WO2006102652A3 (fr) Expression de glycosyltransferases eucaryotiques solubles, actives dans des organismes procaryotiques
WO2002053625A3 (fr) Certains polyethers de silicone, procedes de production et utilisations
USD955226S1 (en) Preserve can
WO2005079870A3 (fr) Installation de sterilisation d'articles par bombardement electronique
CA2465615A1 (fr) Utilisation, dans des compositions cosmetiques, de granules a base de dioxyde de silicium prepare de facon pyrogene
AU2016401A (en) Photocatalytic compositions and methods
WO2008051197A3 (fr) Inhibiteurs de toxine botulinique de type petites molécules
MX2024011115A (es) Enzimas escualeno-hopeno-ciclasa (shc) y variantes de enzimas.
WO2024092160A3 (fr) Protéases bifonctionnelles et leurs utilisations
EP1724477A3 (fr) Dispositif de palier pour un arbre
WO2023220620A3 (fr) Conjugués anticorps-médicament 5t4 et leurs utilisations
HRP20080612T3 (hr) Kombinacija tenofovira, ritonavira i tmc114
WO2001074980A3 (fr) Comprimes d'enzymes pour un nettoyage plus efficace
EP1449965A3 (fr) Vibreur pour compaction du sol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23883774

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23883774

Country of ref document: EP

Kind code of ref document: A2